# Patrick Schöffski

Source: https://onco.cc/people/patrick-schoffski/  
OnCo record `patrick-schoffski` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leuven oncologist who led the trial that showed eribulin lengthens survival in advanced liposarcoma, the basis of the drug's approval for that disease.

## Summary

Patrick Schöffski heads general medical oncology at UZ Leuven and chairs the EORTC soft tissue and bone sarcoma group's early-phase work. He was first author of the 2016 Lancet report of the phase 3 trial in which eribulin improved overall survival compared with dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma, with the benefit concentrated in liposarcoma, leading to eribulin's approval for that indication.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: sarcoma; trialist
- Role: Head of General Medical Oncology, UZ Leuven and Leuven Cancer Institute
- Specialisms: Soft tissue sarcoma; Early-phase drug development; Rare cancers

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Patrick_Sch%C3%B6ffski

## Connected records

- cancers: [Leiomyosarcoma](https://onco.cc/cancers/leiomyosarcoma/), [Liposarcoma](https://onco.cc/cancers/liposarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [UZ Leuven / Leuven Cancer Institute](https://onco.cc/institutions/uz-leuven/)
- key papers: [Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma](https://onco.cc/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/)

---
JSON: https://onco.cc/api/v1/entities/patrick-schoffski.json